Nothing specific. He briefly referred to it, as an innuendo, when we talked about the focus of the company moving forward.
I asked if the company was going to isolate its interest on cancer-related drugs, since the first procurred patent deals with pancreatic and prostrate cancer. That's when he replied it would depend on what was presented to them, as they were not obligating themselves solely to cancer research.
There was definitely no discussion like "we're talking to some people now" or anything like that.......but Martell keeps his cards close to the vest......... I don't think we get anything until a filing.
I am looking forward to the commentary section of the upcoming 10Q
News 
Market Data 
Discover 
